NX210c

DRUG3 trials

Sponsors

Axoltis Pharma

Conditions

Amyotrophic Lateral SclerosisAmyotrophic Lateral Sclerosis (ALS)Healthy Elderly

Phase 1

MAD Study of NX210c

CompletedNCT05827653

Axoltis PharmaHealthy Elderly

Start: 2022-12-05End: 2023-10-02Updated: 2024-12-13

Phase 2

A double-blind, randomized, placebo-controlled, multicentric, phase II study in adult patients with amyotrophic lateral sclerosis (ALS) to assess efficacy, safety, tolerability and pharmacokinetics of multiple intravenous infusions of NX210c.

Active, not recruitingCTIS2023-508895-13-00

Axoltis PharmaAmyotrophic Lateral Sclerosis (ALS)

Start: 2024-10-25Target: 80Updated: 2025-11-06

ALS Phase II Study of NX210c

Active, not recruitingNCT06365216

Axoltis PharmaAmyotrophic Lateral Sclerosis

Start: 2024-10-25End: 2026-09-30Target: 80Updated: 2025-12-24